<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04666948</url>
  </required_header>
  <id_info>
    <org_study_id>BC-5429</org_study_id>
    <nct_id>NCT04666948</nct_id>
  </id_info>
  <brief_title>Precision Dosing of Vancomycin in Critically Ill Children</brief_title>
  <acronym>BENEFICIAL</acronym>
  <official_title>A Multicentric, Randomised Controlled Clinical Trial to Study the Impact of Bedside Model-informed Precision Dosing of Vancomycin in Critically Ill Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Belgium Health Care Knowledge Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ghent University, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this project is to investigate the large-scale utility of MIPD of&#xD;
      vancomycin at point-of-care in ICU children. This evaluation includes a comparison with the&#xD;
      more standard approach on Clinical and patient-oriented measures.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vancomycin is an antibiotic with a narrow therapeutic-toxic margin. This means that the&#xD;
      minimum and maximum target blood target levels differ little from each other. Too low&#xD;
      concentrations will reduce the effect of the antibiotic; higher concentrations may result in&#xD;
      serious side effects, including renal toxicity. Vancomycin dosing tailored to the critically&#xD;
      ill child is challenging.&#xD;
&#xD;
      Currently, the starting dose of vancomycin is calculated on a milligram per kilogram basis,&#xD;
      which is the same for all patients. The dose is then adjusted based on a measured vancomycin&#xD;
      blood concentration (if too high or too low). Despite this measurement, quickly achieving&#xD;
      target concentrations remains a major challenge.&#xD;
&#xD;
      This multicenter, individual randomized study investigates the added value of a user-friendly&#xD;
      computer program for calculating the vancomycin dose in critically ill children, compared to&#xD;
      the current standard-of-care. Specifically, the investigators will study whether the use of&#xD;
      this computer program leads to a shorter time to reach target concentrations, a reduction in&#xD;
      the number and severity of side effects on the kidney, a reduction in patient burden, and a&#xD;
      reduction in time to cure and duration of hospitalization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 28, 2020</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>participants and parents or legal representatives are blinded for the allocation to the intervention or standard-of-care arm until the end of study.&#xD;
the statistician is kept blinded until after data analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients reaching target 24hAUC/MIC</measure>
    <time_frame>24 to 48 hours after start vancomycin treatment</time_frame>
    <description>therapeutic AUC/MIC target range is 400-600</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with (worsening) acute kidney injury during vancomycin treatment</measure>
    <time_frame>from start date of vancomycin treatment until stop date vancomycin treatment or study day 30, whichever comes first</time_frame>
    <description>AKI categories are defined according to the neonatal and pediatric RIFLE criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients reaching target 24h AUC/MIC</measure>
    <time_frame>48-72 hours after start vancomycin treatment</time_frame>
    <description>therapeutic AUC/MIC target range is 400-600</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to clinical cure</measure>
    <time_frame>30 day study period</time_frame>
    <description>Time to clinical cure is defined as the time interval (in days) from start to completion of the vancomycin vancomycin treatment, without recommencement of antibiotics for the same indication within 48h after stop.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ward unit length-of-stay</measure>
    <time_frame>30 day study period</time_frame>
    <description>Ward unit length-of-stay is calculated from day of ward unit admission to day of ward unit discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length-of-stay</measure>
    <time_frame>30 day study period</time_frame>
    <description>Hospital unit length-of-stay is calculated from day of hospital admission to day of hospital discharge.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 day all cause mortality</measure>
    <time_frame>30 day study period</time_frame>
    <description>30 day all cause mortality is measured 30 days after randomisation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cumulative number of additional blood samples during treatment in patients with clinical cure</measure>
    <time_frame>from start date of vancomycin treatment until stop date vancomycin treatment or study day 30, whichever comes first in patients with clinical cure</time_frame>
    <description>An additional blood sample is defined as a sample for vancomycin TDM taken at another timepoint of routine biochemical monitoring samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of additional blood samples to first target attainment during vancomycin treatment</measure>
    <time_frame>from start date of vancomycin treatment until date of first vancomycin target attainment or study day 30, whichever comes first</time_frame>
    <description>An additional blood sample is defined as a sample for vancomycin TDM taken at another timepoint of routine biochemical monitoring samples.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of patients reaching target 24h AUC/MIC</measure>
    <time_frame>72-96 hours after start vancomycin treatment</time_frame>
    <description>therapeutic AUC/MIC target range is 400-600</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of dose adjustments to first target attainment</measure>
    <time_frame>from start date vancomycin treatment until date of first vancomycin target attainment or study day 30, whichever comes first</time_frame>
    <description>Target in Model-Informed Precision Dosing arm: 24h AUC/MIC : 400-600; in comparator arm: target concentration range according to institutional guidelines</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of trough sampling time errors</measure>
    <time_frame>from start date of vancomycin treatment until stop date vancomycin treatment or study day 30, whichever comes first</time_frame>
    <description>only measured for intermittent dosing regimens in the comparator arm.</description>
  </other_outcome>
  <other_outcome>
    <measure>Cumulative vancomycin dose and AUC</measure>
    <time_frame>from start date of vancomycin treatment until stop date vancomycin treatment or study day 30, whichever comes first</time_frame>
    <description>Total cumulative dose and exposure (AUC) during treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">390</enrollment>
  <condition>Vancomycin</condition>
  <arm_group>
    <arm_group_label>Standard of Care Vancomycin treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vancomycin standard-of-care dosing and therapeutic drug monitoring, according to institutional guidelines during 30 day study period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>vancomycin model-informed precision dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Area Under the Concentration (AUC)-time curve/MIC-based model-informed precision dosing of vancomycin using a CE labelled dosing calculator during 30 day study period</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>vancomycin model-informed precision dosing</intervention_name>
    <description>A CE labelled dosing calculator is used for a priori and a posteriori calculation of vancomycin dose using a target AUC between 400-600 mg*h/L</description>
    <arm_group_label>vancomycin model-informed precision dosing</arm_group_label>
    <other_name>dosing calculator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Vancomycin treatment</description>
    <arm_group_label>Standard of Care Vancomycin treatment</arm_group_label>
    <arm_group_label>vancomycin model-informed precision dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age: 0-15 years&#xD;
&#xD;
          -  admitted to ICU or PHO unit&#xD;
&#xD;
          -  suspected or confirmed Gram positive infection&#xD;
&#xD;
          -  planned to start on intravenous intermittent or continuous infusion vancomycin&#xD;
             treatment&#xD;
&#xD;
          -  informed consent signed by parents or legal representatives&#xD;
&#xD;
          -  not previously enrolled in this trial&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  extracorporeal treatment at inclusion or started during treatment (extracorporeal&#xD;
             membrane oxygenation, dialysis, body cooling)&#xD;
&#xD;
          -  n or p RIFLE category failure at inclusion (Day 0) (see section 8.1.2. screening)&#xD;
&#xD;
          -  Known chronic kidney disease as defined by the KDIGO definition as: structural or&#xD;
             functional abnormalities of the kidney regardless of GFR for &lt; 3 months or GFR &lt;&#xD;
             60ml/min/1.73m² for ≥ 3 months. eGFR is estimated using the modified Schwartz equation&#xD;
&#xD;
          -  patient death is deemed imminent and inevitable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pieter De Cock, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pieter De Cock, Prof</last_name>
    <phone>+32 9 332 29 69</phone>
    <email>pieter.decock@uzgent.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anca Amza</last_name>
    <phone>+ 32 9 332 18 83</phone>
    <email>anca.amza@uzgent.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>AZ Sint-Jan Brugge-Oostende AV</name>
      <address>
        <city>Bruges</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander Clarysse, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexander Clarysse, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cliniques universitaires de Saint Luc</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dimitri Van Der Linden, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Dimitri Van Der Linden, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent Houtekie, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier Danhaive, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>An Van Damme, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital universitaire de Reine Fabiola</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Wenderickx</last_name>
    </contact>
    <investigator>
      <last_name>Dominique Biarent</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daphne Vens</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid van Limberghen</last_name>
    </contact>
    <investigator>
      <last_name>Filip Cools, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Reiner Mauel, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jutte van der Werff ten Bosch, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital</name>
      <address>
        <city>Ghent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anca Amza</last_name>
      <phone>+32 9 332 18 83</phone>
      <email>anca.amza@uzgent.be</email>
    </contact>
    <investigator>
      <last_name>Petra Schelstraete, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vicky Bordon, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Vanhaesebrouck, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Evelyn Dhont, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Hermans</last_name>
    </contact>
    <contact_backup>
      <last_name>Erin Anthonio</last_name>
    </contact_backup>
    <investigator>
      <last_name>Anne Smits, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marleen Renard, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>November 28, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 14, 2020</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vancomycin</keyword>
  <keyword>model-informed precision dosing</keyword>
  <keyword>critically ill children</keyword>
  <keyword>dose calculator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

